WO2025119195 - COMBINATION OF POLQ INHIBITOR AND ANTI-CANCER THERAPEUTIC AGENT
National phase entry is expected:
Publication Number
WO/2025/119195
Publication Date
12.06.2025
International Application No.
PCT/CN2024/136593
International Filing Date
04.12.2024
Title **
[English]
COMBINATION OF POLQ INHIBITOR AND ANTI-CANCER THERAPEUTIC AGENT
[French]
COMBINAISON D'UN INHIBITEUR DE POLQ ET D'UN AGENT THÉRAPEUTIQUE ANTICANCÉREUX
Applicants **
DANATLAS PHARMACEUTICALS CO., LTD.
Inventors
ZHOU, Wenlai
ZHUO, Jincong
YAN, Dan
CHEN, Huixian
WANG, Bin
ZHANG, Yan
Priority Data
PCT/CN2023/137577
08.12.2023
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3259 | |
| EPO | Filing, Examination, Granting | 31117 | |
| Japan | Filing, Examination, Granting | 3201 | |
| South Korea | Filing, Examination, Granting | 4396 | |
| USA | Filing, Examination, Granting | 13390 |
Total:
55,363
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Provided herein are combination therapies, and methods of treating diseases and/or conditions with combination therapies; wherein the combination can include PolQ inhibitor and a second anti-cancer therapeutic agent; and the PolQ inhibitor is represented by the compounds of Formula (I).[French]
L'invention concerne des polythérapies, et des méthodes de traitement de maladies et/ou d'états avec des polythérapies; la combinaison pouvant comprendre un inhibiteur de PolQ et un second agent thérapeutique anticancéreux; et l'inhibiteur de PolQ étant représenté par les composés de formule (I).